echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > [weekly] chemical class 1 new anti AIDS drug, first undertaken in China

    [weekly] chemical class 1 new anti AIDS drug, first undertaken in China

    • Last Update: 2016-11-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Zhejiang Pharmaceutical Co., Ltd was sued by Kaneka company of Japan in Germany for infringing the final judgment of product patent related to coenzyme Q10, and Zhejiang Pharmaceutical was compensated 2 Linhai branch of Zhejiang Jiuzhou Pharmaceutical Co., Ltd accepted the comprehensive cGMP on-site inspection of FDA, and passed the certification with zero defects 3 Jiangsu Hengrui Pharmaceutical Co., Ltd has obtained the clinical trial approval documents for four drugs such as indadatro maleate inhalation powder mist 4 Changzhou Pharmaceutical Factory Co., Ltd., a subsidiary of Shanghai Pharmaceutical Group Co., Ltd., applied to the US FDA for the approval of the application for the simplified new drug of rosuvastatin calcium tablets 5 This week (2016.11.07-2016.11.11), 87 drugs (calculated according to the acceptance number, the same below) entered the CDE evaluation center, including 5 traditional Chinese medicine, 65 chemical drugs, 7 biological products and 10 pharmaceutical excipients Acc007 and its tablets (acceptance No.: cxhl1600244, cxhl1600245) are chemical class 1 new drugs declared by Jiangsu Aidi Pharmaceutical Co., Ltd., which have been undertaken by CDE Acc007 is a new type of non nucleoside reverse transcriptase inhibitor, which has been developed for the treatment of HIV After anti-tumor 006 was approved, 007 research also achieved stage success Last year, acc007 completed the first phase of sad and mad clinical research in healthy volunteers in South Korea After data inquiry, there is no more information at home and abroad 2 The special chemical 1.1 new drug sph1188-11 and its tablets (acceptance No.: cxhl1600093, cxhl1600094, cxhl1600095) submitted by Shanghai Pharmaceutical Group Co., Ltd have been reviewed this week Sph1188-11 is independently developed by Shanghai Pharmaceutical It has independent intellectual property rights and applies for compound patent of the drug This product is used for the treatment of non-small cell lung cancer and other malignant tumors According to the data, in 2015, the domestic sales of EGFR inhibitors exceeded 680 million yuan 3 The Anda application of rosuvastatin calcium tablets of Changzhou Pharmaceutical Factory Co., Ltd., a subsidiary of Shanghai Pharmaceutical Group Co., Ltd., was approved by the US FDA Rosuvastatin calcium tablet is a selective hydroxymethylglutaryl coenzyme A reductase inhibitor It is known as "super statins" because of its strong effect on lowering blood lipid, fast and safe It is suitable for primary hypercholesterolemia or mixed dyslipidemia It is also suitable for homozygous familial hypercholesterolemia patients as an adjunctive treatment of diet control and other lipid-lowering measures, or when these methods are not applicable The original manufacturer of this product is AstraZeneca There are 16 manufacturers in the United States with production approval documents of this drug, and 5 in China According to IMS data, the global sales volume of the drug in 2015 was 9.66 billion US dollars, the sales volume in the United States was 6.235 billion US dollars, and the sales volume in China was 2.221 billion yuan This time, SHP was approved to apply for a brief new drug of rosuvastatin calcium tablets, which has brought a positive effect on its development of foreign markets 4 Jiangsu Hengrui Pharmaceutical Co., Ltd applied for the approval of clinical trial of the new chemical 3.1 drug, sakubatravsartan sodium eutectic This product is mainly used to reduce the risk of cardiovascular death and heart failure hospitalization in patients with chronic heart failure accompanied by decreased ejection fraction Sakubatrovalsartan sodium tablet is the first dual inhibitor of angiotensin Ⅱ receptor enkephalinase developed by Novartis It is composed of sakubitral and valsartan crystal according to the amount of substance 1:1 It was approved by the FDA in July 2015, and officially approved by the European Drug Administration in November 2015 for the treatment of patients with chronic heart failure with reduced ejection fraction More than 10 enterprises, such as Jiangsu Wanbang, have applied for class 3.1 clinical trials of the drug In 2015, the global sales volume of sacubatrevalsartan sodium tablets was about USD 17.35 million Note: This article is original by the author of yaozhi.com, welcome to reprint, please indicate the source and author when reprint, thank you!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.